KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
OnApril 24, 2019, KemPharm, Inc. (the Company) held its 2019 Annual Meeting of Stockholders (the 2019 Annual Meeting), for the following purposes:
Of the26,675,552 shares outstanding as of the record date,22,545,890 shares, or 84.52%, were present or represented by proxy at the 2019 Annual Meeting. At the 2019 Annual Meeting, each ofTravis C. Mickle, Ph.D.andDanny L. Thompsonwas re-elected as a director of the Company. The stockholders of the Company ratified the appointment ofRSM USLLP as the Companys independent registered public accounting firm for the Companys fiscal year ending December 31, 2019. The final voting results on each of the matters submitted to a vote of stockholders at the 2019 Annual Meeting were as follows:
About KemPharm, Inc. (NASDAQ:KMPH)
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company’s products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
